Electronic Version v1.1 Stylesheet Version v1.1

 SUBMISSION TYPE:
 NEW ASSIGNMENT

 NATURE OF CONVEYANCE:
 ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
eNOS Pharmaceuticals, Inc.	08/14/2007

RECEIVING PARTY DATA

Name:	Palmetto Pharmaceuticals, LLC	
Street Address:	217 Medinah	
City:	Saint Simons Island	
State/Country:	GEORGIA	
Postal Code:	31522	

PROPERTY NUMBERS Total: 13

Property Type	Number
Application Number:	09955485
Application Number:	10952533
Application Number:	11042599
Application Number:	11125308
Application Number:	11388758
Application Number:	11042017
Application Number:	11107395
PCT Number:	US0313689
PCT Number:	US0007089
PCT Number:	US0333931
PCT Number:	US0613805
PCT Number:	US0413255
PCT Number:	US0602127

CORRESPONDENCE DATA

PATENT REEL: 019801 FRAME: 0612

500350378

Fax Number: (617)832-7000

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 617-832-1264

Email: dsmith@foleyhoag.com

Correspondent Name: DeAnn Smith

Address Line 1: 155 Seaport Boulevard

Address Line 4: Boston, MASSACHUSETTS 02210-2600

ATTORNEY DOCKET NUMBER: 25988.00501

NAME OF SUBMITTER: DeAnn Smith

Total Attachments: 6

source=AssignmentPalmetto#page1.tif source=AssignmentPalmetto#page2.tif source=AssignmentPalmetto#page3.tif source=AssignmentPalmetto#page4.tif source=AssignmentPalmetto#page5.tif source=AssignmentPalmetto#page6.tif

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT ("Assignment"), dated as of August 14, 2007, is entered into by and between eNOS Pharmaceuticals, Inc., a Delaware corporation, having an address of 7 Coach Road, Lexington, MA 02420-1101 ("Assignor"), and Palmetto Pharmaceuticals, LLC, a Delaware limited liability company, having an address of 217 Medinah, Saint Simons Island, Georgia 31522 ("Assignee").

RECITALS

- A. Assignor is the owner of certain patents and patent applications in the United States Patent and Trademark Office and outside the United States identified on <u>Schedule A</u> attached hereto (the "<u>Patent Rights</u>"); and
- B. Assignor and Assignee have entered into an Asset Purchase Agreement, dated as of August 14, 2007 (the "Asset Purchase Agreement"), pursuant to which Assignor has agreed to assign, sell and transfer all of the Patent Rights unto Assignee;

NOW, THEREFORE, for good and valuable consideration, the receipt, sufficiency and adequacy of which are hereby acknowledged, Assignor does hereby sell, assign and transfer unto the Assignee, its successors and assigns, the entire and exclusive right, title and interest in and to the Patent Rights, including but not limited to, all rights, title and interest in and to all inventions disclosed or claimed therein, in the United States and throughout the world (with priority rights), and in and to any continuations, continuations-in-part, divisions, reissues, re-examinations, extensions and foreign counterparts, and including, without limitation, all claims for damages by reason of past infringement, with the right to sue for and collect the same.

Assignor agrees, without further consideration, to execute (or to require its employees or consultants to execute, upon request by Assignee) all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to Assignee the right, title and interest conveyed herein, and to take such further actions as may be reasonably requested by Assignee in order to carry out the provisions and purposes of this Assignment including, without limitation, to execute one or more further assignments covering the Patent Rights in a form acceptable for recordation in both the United States Patent and Trademark Office and in foreign patent offices.

[Remainder of Page Intentionally Left Blank]

The foregoing assignment is hereby made	as of the day of August, 2007.
	ENOS PHARMACEUTICALS, INC.
	Name: Cynthia Doe:
STATE OF TEXAS COUNTY OF HARAS	۱۳۳۰ کرلاردای
acknowledged that he/she is the him to	the person who signed this instrument, who of eNOS Pharmaceuticals, Inc. and such instrument as a free act on behalf of
	Notato Public
	My Commission Expires: 10 8 2000 NOTSNA D GORADIA My Commission Expires October 6, 2009
The foregoing assignment is accepted as of	the day of August, 2007.
:	PALMETTO PHARMACEUTICALS, LLC
	By: Name: Title:
STATE OF	
appeared, the	efore me on this day of August, 2007, the person who signed this instrument, who of Palmetto Pharmaceuticals, the signed such instrument as a free act on
	Notary Public
	My Commission Expires:

	ENOS PHARMACEUTICALS, INC.
	By: Name: Title:
STATE OF	:
2007, appearedwho acknowledged that he/she is t	N to before me on this day of , the person who signed this instrument the of eNOS Pharmaceuticals he/she signed such instrument as a free act or c.
	Notary Public
	My Commission Expires:
The foregoing assignment is accepted	d as of the <u>14</u> day of August, 2007. Palmetto Pharmaceuticals, LLC
STATE OF GEORGIC	* · · · · · · · · · · · · · · · · · · ·
appeared <u>Timothy TamicSon</u> acknowledged that he/she is the/a _	PALMETTO PHARMACEUTICALS, LLC By:

PATENT

13

REEL: 019801 FRAME: 0616

SCHEDULE A

PATENTS

Issued Patents

Country/	Application	Publication No./Date	Patent No./ Date	Title
Status	No./Date			
USA	09/955485	20030032616-A1	6818669	INCREASING CEREBRAL
				BIOAVAILABILITY OF
Granted,	09/19/2001	02/13/2003	11/16/2004	DRUGS
expires				
03/20/2020				
New Zealand	539672		539672	SUSTAINED RELEASE L-
				ARGININE FORMULATIONS
Granted,	10/24/2003	09/29/2006	01/11/2007	AND METHODS OF
,	10,2 ,2003	05/25/2000	01/11/2007	MANUFACTURE AND USE
expires				WANGIACIONE AND OBE
10/24/2023				

Patents Applications

Country/	Application	Publication	Title
Status	No./Date	No./Date	
PCT	US03/013689	03/094909	METHODS AND COMPOSITIONS FOR
			THE TREATMENT AND
Completed	05/02/2003	11/20/2003	PREVENTION OF INTERMITTENT
_			CLAUDICATION OR ALZHEIMER'S
			DISEASE
USA	10/952533	20050106269-A1	INCREASING CEREBRAL
			BIOAVAILABILITY OF DRUGS
Published	09/28/2004	05/19/2005	
PCT	US00/07089	WO00/56328	INCREASING CEREBRAL
			BIOAVAILABILITY OF DRUGS
Nationalized	03/20/2000	09/28/2000	
Canada	2367002	no information	INCREASING CEREBRAL
		listed	BIOAVAILABILITY OF DRUGS
Pending	03/20/2000		
USA	11/042599	20050287210-A1	SUSTAINED RELEASE L-ARGININE
			FORMULATIONS AND METHODS OF
Published	01/24/2005	12/29/2005	MANUFACTURE AND USE
USA	11/125308	20060029668-A1	SUSTAINED RELEASE L-ARGININE
			FORMULATIONS AND METHODS OF
Published	05/09/2005	02/09/2006	MANUFACTURE AND USE
PCT	US03/33931	04/037203	SUSTAINED RELEASE L-ARGININE

		T	TODAGU ATIONG AND METHODS OF
37.1	10/04/0000	05/06/0004	FORMULATIONS AND METHODS OF
Nationalized	10/24/2003	05/06/2004	MANUFACTURE AND USE
PCT	US06/013805	06/124161	SUSTAINED RELEASE L-ARGININE
	24/12/2006	11/00/0006	FORMULATIONS AND METHODS OF
Published	04/13/2006	11/23/2006	MANUFACTURE AND USE
China	200380107369.2	1731985	SUSTAINED RELEASE L-ARGININE
			FORMULATIONS AND METHODS OF
Published	10/24/2003	02/08/2006	MANUFACTURE AND USE
Japan	2005-501690		SUSTAINED RELEASE L-ARGININE
			FORMULATIONS AND METHODS OF
Pending	10/24/2003		MANUFACTURE AND USE
Korea	2005-0007175	KR5083827A	SUSTAINED RELEASE L-ARGININE
			FORMULATIONS AND METHODS OF
Published	1/26/2005	8/26/2005	MANUFACTURE AND USE
Australia	2003284962		SUSTAINED RELEASE L-ARGININE
			FORMULATIONS AND METHODS OF
Pending	10/24/2003		MANUFACTURE AND USE
Canada	2503284		SUSTAINED RELEASE L-ARGININE
			FORMULATIONS AND METHODS OF
Pending	10/24/2003		MANUFACTURE AND USE
Mexico	2005/004290		SUSTAINED RELEASE L-ARGININE
			FORMULATIONS AND METHODS OF
Pending	10/24/2003		MANUFACTURE AND USE
Philippines	12005500769		SUSTAINED RELEASE L-ARGININE
			FORMULATIONS AND METHODS OF
Published	10/24/2003		MANUFACTURE AND USE
India	983/CHENP/2005	}	SUSTAINED RELEASE L-ARGININE
			FORMULATIONS AND METHODS OF
Pending	10/24/2003		MANUFACTURE AND USE
European	03779284.3	1562555	SUSTAINED RELEASE L-ARGININE
Patent			FORMULATIONS AND METHODS OF
Convention	10/24/2003	08/17/2005	MANUFACTURE AND USE
Published			
Singapore	200502463-3		SUSTAINED RELEASE L-ARGININE
			FORMULATIONS AND METHODS OF
Pending	10/24/2003		MANUFACTURE AND USE
USA	11/388758		SUSTAINED RELEASE L-ARGININE
			FORMULATIONS AND METHODS OF
Pending	03/24/2006		MANUFACTURE AND USE
PCT	US04/013255	05/035001	SUSTAINED RELEASE L-ARGININE
			FORMULATIONS AND METHODS OF
Nationalized	04/28/2004	04/21/2005	MANUFACTURE AND USE
Japan	2006-527960		SUSTAINED RELEASE L-ARGININE
-			FORMULATIONS AND METHODS OF
Pending	04/28/2004		MANUFACTURE AND USE

Australia/	2004279298		SUSTAINED RELEASE L-ARGININE
			FORMULATIONS AND METHODS OF
Pending	04/28/2004		MANUFACTURE AND USE
New	546704		SUSTAINED RELEASE L-ARGININE
Zealand			FORMULATIONS AND METHODS OF
	04/28/2004		MANUFACTURE AND USE
Pending			
Canada	2540202		SUSTAINED RELEASE L-ARGININE
			FORMULATIONS AND METHODS OF
Pending	04/28/2004		MANUFACTURE AND USE
European	04750925.2	1675619	SUSTAINED RELEASE L-ARGININE
Patent			FORMULATIONS AND METHODS OF
Convention	04/28/2004	07/05/2006	MANUFACTURE AND USE
Published			
USA	11/042017	20050288372-A1	METHODS OF TREATING VARIOUS
			CONDITIONS BY ADMINISTRATION
Published	01/24/2005	12/29/2005	OF SUSTAINED RELEASED L-
			ARGININE
USA	11/107395	20050288373-A1	METHODS OF TREATING VARIOUS
			CONDITIONS BY ADMINISTRATION
Published	04/14/2005	12/29/2005	OF SUSTAINED RELEASED L-
			ARGININE
PCT	US06/002127	06/081147	METHODS OF TREATING VARIOUS
			CONDITIONS BY ADMINISTRATION
Published	01/23/2006	08/03/2006	OF SUSTAINED RELEASED L-
			ARGININE

PATENT REEL: 019801 FRAME: 0619

RECORDED: 09/10/2007